^
Association details:
| Biomarker: | CCNE1 overexpression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety, anti-tumor activity, and biomarker analysis in a phase 1 trial of the once-daily Wee1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
Published date:
04/16/2021
Excerpt:
Six patients (14%) had confirmed partial responses (PR): 4 ovarian, 2 endometrial….We determined the once-daily adavosertib RPh2D and observed activity in patients with ovarian or endometrial carcinoma, including 2 with baseline CCNE1 mRNA overexpression.
DOI:
10.1158/1078-0432.CCR-21-0329
